| Literature DB >> 22984522 |
Ju-Sheng Zheng1, Tao Huang, Jing Yang, Yuan-Qing Fu, Duo Li.
Abstract
BACKGROUND: Prospective cohort studies in relation to the associations between n-3 polyunsaturated fatty acids (PUFA) and risk of type 2 diabetes (T2D) were inconsistent. Differences in tissue n-3 PUFA compositions in subjects with and without T2D were also inconsistent in both cohort and case-control studies. We conducted a systematic review and meta-analysis of prospective cohort studies to examine the associations of fish and n-3 PUFA intake with T2D risk. The differences in tissue n-3 PUFA compositions in subjects with and without T2D were investigated based on cohort and case-control studies. METHODS ANDEntities:
Mesh:
Substances:
Year: 2012 PMID: 22984522 PMCID: PMC3439396 DOI: 10.1371/journal.pone.0044525
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1PRISMA flow diagram for selection of studies in the meta-analysis.
Characteristics of included prospective cohort studies in the meta-analysis of dietary fish and n-3 polyunsaturated fatty acid intake and type 2 diabetes.
| Study source | Duration of follow-up (years) | Age (y) | No. of cases/size of cohort | Fish or n-3 PUFA type | Exposure range (g/d) | Adjusted RR (95% CI) | Adjusted variables |
| Meyer et al, 2001 (3) | 11 | 55–69 | 1890/35988 | LC n-3 PUFA | Highest: 0.39; ref: 0.03 | 1.11 (0.94, 1.30) | Age, total energy, WHR, BMI, physical activity, cigarette smoking, alcohol consumption, education, marital status, residential area, hormone replacement therapy, energy-adjusted dietary magnesium and cereal fiber, dietary protein, saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, |
| van Dam et al, 2002 (29) | 12 | 40–75 | 1321/42504 | C18∶3n-3 | Highest: 0.671; ref: 0.321 | 0.93 (0.78, 1.11) | Age, total energy intake, time period, physical activity, cigarette smoking, alcohol consumption, hypercholesterolemia, hypertension, family history of type 2 diabetes, intake of cereal fiber and magnesium and BMI |
| Hodge et al, 2007 (5) | 4 | 36–72 | 364/3737 | C22∶6n-3 | Highest: Q5; ref: Q1 | 0.77 (0.52, 1.16) | Age, sex, country of birth, family history of diabetes, physical activity, alcohol intake, BMI, and waist-hip ratio |
| C20∶5n-3 | Highest: Q5; ref: Q1 | 0.68 (0.62, 1.34) | |||||
| C18∶3n-3 | Highest: Q5; ref: Q1 | 1.14 (0.75, 1.73) | |||||
| Kaushik et al_Nurses’ Health Study, 2009 (6) | 18 | 30–55 | 4159/61031 | LC n-3 PUFA | Highest: 0.49; ref: 0.06 | 1.23 (1.11, 1.37) | Smoking, alcohol consumption, physical activity, family history of diabetes mellitus, BMI, intakes of saturated fat, trans fats, linolenic acid, linoleic acid, caffeine, cereal fiber, glycemic index, calories, menopausal status, and postmenopausal hormone use |
| Fish | Highest: ≥5 times/wk; ref: <1 time/mo | 1.29 (1.05, 1.57) | |||||
| Kaushik et al_Nurses’ Health Study 2, 2009 (6) | 14 | 26–46 | 2728/91669 | LC n-3 PUFA | Highest: 0.36; ref: 0.06 | 1.25 (1.10, 1.42) | Smoking, alcohol consumption, physical activity, family history of diabetes mellitus, BMI, intakes of saturated fat, trans fats, linolenic acid, linoleic acid, caffeine, cereal fiber, glycemic index, calories, use of hormone replacement therapy and oral contraceptive use |
| Fish | Highest: ≥5 times/wk; ref: <1 time/mo | 1.32 (0.99, 1.74) | |||||
| Kaushik et al_Health Professionals Follow-up Study, 2009 (6) | 18 | 39–78 | 2493/42504 | LC n-3 PUFA | Highest: 0.62; ref: 0.09 | 1.12 (0.98, 1.28) | Smoking, alcohol consumption, physical activity, family history of diabetes mellitus, BMI, intakes of saturated fat, trans fats, linolenic acid, linoleic acid, caffeine, cereal fiber, glycemic index, and calories |
| Fish | Highest: ≥5 times/wk; ref: <1 time/mo | 1.16 (0.96, 1.41) | |||||
| van Woudenbergh et al, 2009 (7) | 15 | ≥55 | 463/4472 | C22∶6n-3+ C20∶5n-3 | Highest: 0.2368; ref: 0.0238 | 1.05 (0.80, 1.38) | Age, sex, smoking, education level, intake of energy, alcohol, trans fatty acid, fiber, intake of selenium, vitamin D and cholesterol |
| Total fish | Highest: 35.6; ref: 0 | 1.32 (1.02, 1.70) | Age sex, smoking, education level, intake of energy, alcohol, trans fatty acid, and fiber | ||||
| Fatty fish | Highest: ≥15.7; ref: 0 | 0.99 (0.71, 1.38) | Age sex, smoking, education level, intake of energy, alcohol, trans fatty acid, fiber and lean fish | ||||
| Lean fish | Highest: 30.6; ref: 0 | 1.30 (1.01, 1.68) | Age sex, smoking, education level, intake of energy, alcohol, trans fatty acid, fiber and fatty fish | ||||
| Patel et al, 2009 (14) | 10.2 | 40–79 | 725/21984 | Total fish | Highest: ≥1 portion/wk; ref: <1 portion/wk | 0.75 (0.58, 0.96) | Age, sex, family history of diabetes, smoking, education level, physical activity, total energy intake, alcohol intake, plasma vitamin C, BMI, and waist circumference |
| Oily fish | Highest: ≥1 portion/wk; ref: <1 portion/wk | 0.94 (0.78, 1.13) | |||||
| White fish | Highest: ≥1 portion/wk; ref: <1 portion/wk | 0.87 (0.73, 1.03) | |||||
| Shellfish | Highest: ≥1 portion/wk; ref: <1 portion/wk | 1.36 (1.02, 1.81) | |||||
| Djousse et al_Women’s Health Study, 2011 (9) | 12.4 | ≥45 | 2370/36328 | Marine n-3 PUFA | Highest: 0.43; ref: 0.07 | 1.44 (1.25, 1.65) | Age, BMI, parental history of diabetes, smoking, exercise, alcohol intake, menopausal status, red-meat intake, and quintiles of energy intake, linoleic acid, α-linolenic acid, dietary magnesium, trans fat, saturated fat, cereal fiber, and glycemic index |
| C18∶3n-3 | Highest: 1.59; ref: 0.79 | 1.01 (0.85, 1.21) | |||||
| Fish | Highest: 3.93 servings/wk; ref: 0.47 servings/wk | 1.49 (1.30, 1.70) | |||||
| Djousse et al_Cardiovascular Health Study, 2011 (8) | 10.6 | ≥65 | 204/3088 | C22∶6n-3+ C20∶5n-3 | Highest: >0.56; ref: ≤0.17 | 1.04 (0.67, 1.60) | Age, race, sex, clinic site, BMI, alcohol consumption, physical activity, current smoking, LDL cholesterol, and linoleic acid |
| C18∶3n-3 | Highest: >0.18; ref: ≤0.11 | 0.50 (0.24, 1.05) | |||||
| Fish | Highest: ≥5/wk; ref: <1/mo | 1.07 (0.35, 3.30) | Age, race, sex, clinic site, BMI, alcohol consumption, physical activity, current smoking, total energy intake and LDL cholesterol | ||||
| Nanri et al_men, 2011 (15) | 5 | 45–75 | 572/22921 | Oily fish | Highest: 71.2; ref: 10.7 | 0.79 (0.59, 1.05) | Age, study area, BMI, smoking status, alcohol consumption, family history of diabetes mellitus, total physical activity, history of hypertension, total energy intake, coffee consumption, intake of calcium, magnesium, dietary fiber, vegetable, fruit, meat, and rice |
| Lean fish | Highest: 30; ref: 3.3 | 1.05 (0.80, 1.38) | |||||
| Nanri et al_women, 2011 (15) | 5 | 45–75 | 399/29759 | Oily fish | Highest: 68.1; ref: 10.7 | 0.93 (0.67, 1.29) | The same as above |
| Lean fish | Highest: 23.3; ref: 2.7 | 1.02 (0.75, 1.40) | |||||
| Villegas et al_men, 2011 (10) | 4.1 | 40–74 | 900/51963 | LC n-3 PUFA | Highest: 0.2; ref: 0.02 | 0.89 (0.70, 1.12) | Age, energy intake, waist-to-hip ratio, BMI, smoking, alcohol consumption, physical activity, income level, educational level, occupation, family history of diabetes, hypertension and dietary pattern |
| Fish | Highest: 79; ref: 9.7 | 0.94 (0.74, 1.17) | |||||
| shellfish | Highest: 24.3; ref: 1.6 | 0.82 (0.65, 1.02) | |||||
| Villegas et al_women, 2011 (10) | 8.9 | 40–70 | 3034/64193 | LC n-3 PUFA | Highest: 0.2; ref: 0.02 | 0.84 (0.74, 0.95) | The same as above |
| Fish | Highest: 80.2; ref: 9.5 | 0.89 (0.78, 1.01) | |||||
| shellfish | Highest: 23.5; ref: 1.4 | 0.86 (0.76, 0.99) | |||||
| Brostow et al, 2011 (11) | 5.7 | 45–74 | 2252/43176 | C22∶6n-3+ C20∶5n-3 | Highest: 0.6; ref: 0.11 | 0.93 (0.77, 1.11) | Age, sex, dialect, year of interview, educational level, BMI, physical activity, smoking status, alcohol use, hypertension, intakes of omega-6, alternate omega-3, monounsaturated fat, saturated fat, dietary fiber, protein, and total energy |
| C18∶3n-3 | Highest: 1.06; ref: 0.27 | 0.79 (0.67, 0.93) | |||||
| Kroger et al, 2011 (27) | 7 | 35–65 | 673/2724 | LC n-3 PUFA | Highest: 0.59; ref: 0.04 (% of total fat intake) | 1.29 (0.95, 1.75) | Age, sex, BMI, waist circumference, cycling, sports activity, education, smoking status, alcohol intake, occupational activity, coffee intake, fiber intake, total fat intake and energy intake |
| C18∶3n-3 | Highest: 2.6; ref: 1.4 (% of total fat intake) | 1.13 (0.80, 1.59) |
Abbreviations: Q: quintile; ref: reference; LC n-3 PUFA: long-chain n-3 polyunsaturated fatty acids (C22∶6n–3+ C20∶5n-3).
Characteristics of included studies in the meta-analysis of different n-3 polyunsaturated fatty acids compositions between subjects with and without type 2 diabetes.
| Study source | Mean age(years) | Study design | No. of cases | No. of controls | Tissue n-3 PUFAs composition (% of totalfatty acids, case vs controls) |
| Faas et al, 1988 (20) | 48.5 | Case-control | 5 | 5 | Plasma C22∶6n-3 (1.6±0.7 vs 1.5±0.5) |
| Red blood cell C22∶6n-3 (4.4±1.1 vs 4.4±1.1) | |||||
| Bohov et al, 1993 (21) | 60.6 | Case-control | 183 | 114 | Serum C22∶6n-3 (1.96±0.05 vs 1.67±0.06) |
| Serum C20∶5n-3 (0.66±0.03 vs 0.62±0.03) | |||||
| Serum C18∶3n-3 (0.42±0.01 vs 0.55±0.01) | |||||
| Serum n-3 PUFA (3.53±0.08 vs 3.31±0.09) | |||||
| Pelikanova et al, 2001 (22) | 40.4 | Case-control | 21 | 24 | Serum PL C22∶6n-3 (3.04±0.87 vs 2.11±0.49) |
| Serum PL C20∶5n-3 (1.04±0.54 vs 0.82±0.41) | |||||
| Serum PL C18∶3n-3 (0.20±0.19 vs 0.29±0.14) | |||||
| Serum PL n-3 PUFA (5.40±1.75 vs 4.67±1.39) | |||||
| Rodriguez et al, 2004 (19) | 53 | Case-control | 13 | 13 | Plasma PL C22∶6n-3 (4.01±0.80 vs 3.47±0.89) |
| Plasma PL C20∶5n-3 (0.64±0.23 vs 0.74±0.35) | |||||
| Plasma PL C18∶3n-3 (0.18±0.13 vs 0.20±0.13) | |||||
| Plasma PL n-3 PUFA (5.96±0.73 vs 5.49±1.17) | |||||
| Red blood cell PL C22∶6n-3 (3.9±1.35 vs 3.91±0.71) | |||||
| Red blood cell PL C20∶5n-3 (0.52±0.23 vs 0.44±0.12) | |||||
| Red blood cell PL C18∶3n-3 (0.15±0.04 vs 0.15±0.06) | |||||
| Red blood cell PL n-3 PUFA (7.18±1.71 vs 5.94±1.15) | |||||
| Bakan et al, 2006 (34) | 56.5 | Case-control | 32 | 20 | Plasma C22∶6n-3 (1.9±0.9 vs 2.7±0.4) |
| Mao et al, 2007 (30) | 57.4 | Case-control | 62 | 53 | Serum PL C22∶6n-3 (5.1±1.3 vs 6.4±1.1) |
| Serum PL C20∶5n-3 (1.9±0.6 vs 1.9±0.5) | |||||
| Serum PL C18∶3n-3 (0.32±0.2 vs 0.33±0.13) | |||||
| Serum PL n-3 PUFA (8.2±1.6 vs 9.6±1.5) | |||||
| Krachler et al, 2008 (17) | 51.6 | Case-control | 159 | 291 | Erythrocyte membrane C22∶6n-3 (4.61±1.01 vs 4.83±1.02) |
| Erythrocyte membrane C20∶5n-3 (1.31±0.45 vs 1.37±0.46) | |||||
| Erythrocyte membrane C18∶3n-3 (0.35±0.10 vs 0.36±0.13) | |||||
| Lou et al, 2010 (31) | 56.1 | Case-control | 60 | 55 | Serum PL C22∶6n-3 (4.11±1.32 vs 6.41±1.26) |
| Serum PL C20∶5n-3 (1.80±0.55 vs 1.90±0.52) | |||||
| Serum PL C18∶3n-3 (0.28±0.08 vs 0.33±0.10) | |||||
| Serum PL n-3 PUFA (6.08±1.66 vs 9.54±1.54) | |||||
| Huang et al, 2010 (16) | 60 | Case-control | 180 | 186 | Plasma PL C22∶6n-3 (2.46±2.2 vs 5.8±2.0) |
| Plasma PL C20∶5n-3 (0.99±0.5 vs 2.12±0.7) | |||||
| Plasma PL C18∶3n-3 (0.36±0.1 vs 0.70±0.2) | |||||
| Plasma PL n-3 PUFA (4.52±2.8 vs 9.22±1.8) | |||||
| Zhang et al, 2011 (32) | 49.2 | Case-control | 241 | 156 | Plasma total n-3 PUFA (5.52±0.77 vs 6.47±2.27) |
| Vessby et al, 1994 (33) | 50 | Prospective cohort | 75 | 1753 | Serum CE C22∶6n-3 (0.68±0.21 vs 0.70±0.21) |
| Serum CE C20∶5n-3 (1.42±0.57 vs 1.35±0.63) | |||||
| Serum CE C18∶3n-3 (0.65±0.18 vs 0.66±0.16) | |||||
| Wang et al, 2003 (18) | 52 | Prospective cohort | 252 | 2657 | Plasma PL C22∶6n-3 (2.71±0.83 vs 2.76±0.84) |
| Plasma PL C20∶5n-3 (0.58±0.33 vs 0.56±0.31) | |||||
| Plasma PL C18∶3n-3 (0.13±0.05 vs 0.15±0.05) | |||||
| Plasma CE C22∶6n-3 (0.43±0.15 vs 0.43±0.15) | |||||
| Plasma CE C20∶5n-3 (0.59±0.36 vs 0.54±0.28) | |||||
| Plasma CE C18∶3n-3 (0.4±0.11 vs 0.42±0.11) | |||||
| Hodge et al, 2007 (5) | 56.2 | Prospective cohort | 346 | 3391 | Plasma PL C22∶6n-3 (4.15±0.99 vs 4.02±1.07) |
| Plasma PL C20∶5n-3 (1.15±0.50 vs 1.05±0.47) | |||||
| Plasma PL C18∶3n-3 (0.17±0.08 vs 0.17±0.08) | |||||
| Plasma PL n-3 PUFA (6.77±1.36 vs 6.55±1.40) |
Abbreviations: n-3 PUFAs: n-3 polyunsaturated fatty acids; PL: phospholipids; CE: cholesterol esters.
Figure 2Relative risk of type 2 diabetes for highest vs lowest categories of total fish intake.
The combined relative risk was achieved using random-effects model. Grey square represents relative risk in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. The diamond indicates summary risk estimate.
Subgroup analyses for the associations of fish intake with risk of type 2 diabetes according to standardized fish intake categories (high, moderate and low).
| Fish intake classification | No. of cohorts | RR (95% CI) |
|
|
|
| 8 | 1.03 (0.9, 1.19) | 0.011 | 61.6 |
| Regions | ||||
| Asian countries | 4 | 0.89 (0.81, 0.98) | 0.815 | 0 |
| Western countries | 4 | 1.24 (1.09, 1.40) | 0.834 | 0 |
| US | 4 | 1.24 (1.09, 1.40) | 0.834 | 0 |
| Follow-up duration | ||||
| >9.9 years | 4 | 1.24 (1.09, 1.40) | 0.834 | 0 |
| ≤9.9 years | 4 | 0.89 (0.81, 0.98) | 0.815 | 0 |
| Gender | ||||
| Men | 3 | 0.97 (0.78, 1.21) | 0.077 | 61.1 |
| Women | 4 | 1.08 (0.86, 1.36) | 0.005 | 77 |
| Both | 1 | 1.07 (0.35, 3.29) | ||
|
| 10 | 1.06 (0.90, 1.25) | <0.001 | 89 |
| Regions | ||||
| Asian countries | 4 | 0.83 (0.78, 0.89) | 0.934 | 0 |
| Western countries | 6 | 1.25 (1.12, 1.40) | 0.067 | 51.4 |
| Europe | 1 | 1.32 (1.02, 1.70) | ||
| US | 5 | 1.24 (1.09, 1.42) | 0.038 | 60.7 |
| Follow-up duration | ||||
| >9.9 years | 6 | 1.25 (1.12, 1.40) | 0.067 | 51.4 |
| ≤9.9 years | 4 | 0.83 (0.78, 0.89) | 0.934 | 0 |
| Gender | ||||
| Men | 3 | 0.94 (0.78, 1.13) | 0.038 | 69.4 |
| Women | 5 | 1.10 (0.84, 1.44) | <0.001 | 94.2 |
| Both | 2 | 1.28 (1.00, 1.64) | 0.434 | 0 |
|
| 10 | 1.05 (0.97, 1.13) | 0.016 | 55.8 |
| Regions | ||||
| Asian countries | 4 | 0.96 (0.88, 1.04) | 0.92 | 0 |
| Western countries | 6 | 1.11 (1.03, 1.20) | 0.121 | 42.6 |
| Europe | 1 | 1.19 (0.92, 1.54) | ||
| US | 5 | 1.10 (1.01, 1.20) | 0.073 | 53.2 |
| Follow-up duration | ||||
| >9.9 years | 6 | 1.11 (1.03, 1.20) | 0.121 | 42.6 |
| ≤9.9 years | 4 | 0.96 (0.88, 1.04) | 0.92 | 0 |
| Gender | ||||
| Men | 3 | 0.97 (0.88, 1.06) | 0.812 | 0 |
| Women | 5 | 1.08 (0.98, 1.20) | 0.01 | 69.8 |
| Both | 2 | 1.17 (0.92, 1.48) | 0.646 | 0 |
Figure 3Relative risk of type 2 diabetes for highest vs lowest categories of marine n-3 polyunsaturated fatty acids intake.
The combined relative risk was achieved using random-effects model. Grey square represents relative risk in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. The diamond indicates summary risk estimate.
Figure 4Relative risk of type 2 diabetes for highest vs lowest categories of alpha-linolenic acid intake.
The combined relative risk was achieved using random-effects model. Grey square represents relative risk in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. The diamond indicates summary risk estimate.
Subgroup analyses on different tissue n-3 polyunsaturated fatty acid compositions in subjects with and without type 2 diabetes.
| N-3 PUFAs | No. of studies | SMD (95% CI) |
|
|
| C22∶6n-3 | 12 | −0.31 (−0.70, 0.07) | <0.001 | 96.4 |
| Asian countries | 4 | −1.43 (−1.75, −1.12) | 0.051 | 61.3 |
| Western countries | 8 | 0.16 (−0.05, 0.37) | <0.001 | 82.8 |
| C20∶5n-3 | 10 | −0.16 (−0.53, 0.21) | <0.001 | 96.3 |
| Asian countries | 4 | −0.69 (−1.96, 0.59) | <0.001 | 97.9 |
| Western countries | 6 | 0.09 (−0.03, 0.20) | 0.055 | 51.3 |
| C18∶3n-3 | 10 | −0.48 (−0.86, −0.11) | <0.001 | 96.5 |
| Asian countries | 3 | −0.92 (−2.27, 0.42) | <0.001 | 98.0 |
| Western countries | 7 | −0.27 (−0.50, −0.05) | <0.001 | 87.2 |
| Total n-3 PUFA | 8 | −0.56 (−1.22, 0.09) | <0.001 | 98.0 |
| Asian countries | 4 | −1.41 (−2.23, −0.59) | <0.001 | 96.7 |
| Western countries | 4 | 0.18 (0.08, 0.28) | 0.638 | 0 |
Abbreviations: n-3 PUFAs: n-3 polyunsaturated fatty acids; SMD: standardized mean difference.
Subgroup analyses on fish and marine n-3 polyunsaturated fatty acids intake and risk of type 2 diabetes.
| Fish intake and risk of T2D | Marine n-3 PUFA (C22∶6n-3+ C20∶5n-3) and risk of T2D | |||||||
| Group | No. of cohorts | RR (95% CI) |
|
| No. of cohorts | RR (95% CI) |
|
|
| All studies | 11 | 1.07 (0.91, 1.25) | <0.001 | 81.1 | 12 | 1.07 (0.95, 1.20) | <0.001 | 80.8 |
| Regions | ||||||||
| Asian countries | 4 | 0.89 (0.81, 0.98) | 0.815 | 0 | 3 | 0.87 (0.79, 0.96) | 0.654 | 0 |
| Western countries | 7 | 1.20 (1.01, 1.44) | 0.001 | 74.3 | 9 | 1.16 (1.04, 1.28) | 0.002 | 66.8 |
| Europe | 2 | 1.00 (0.57, 1.73) | 0.002 | 89.5 | 2 | 1.15 (0.94, 1.41) | 0.324 | 0 |
| US | 5 | 1.33 (1.20, 1.48) | 0.302 | 17.6 | 6 | 1.22 (1.13, 1.33) | 0.109 | 44.5 |
| Follow-up duration | ||||||||
| >9.9 years | 7 | 1.20 (1.01, 1.44) | 0.001 | 74.3 | 7 | 1.21 (1.12, 1.31) | 0.116 | 41.2 |
| ≤9.9 years | 4 | 0.89 (0.81, 0.98) | 0.815 | 0 | 5 | 0.90 (0.78, 1.04) | 0.061 | 55.5 |
| Gender | ||||||||
| Men | 3 | 0.97 (0.78, 1.21) | 0.077 | 61.1 | 2 | 1.02 (0.82, 1.27) | 0.096 | 64 |
| Women | 5 | 1.17 (0.91, 1.49) | <0.001 | 87.9 | 5 | 1.16 (0.97, 1.38) | <0.001 | 89.4 |
| Both | 3 | 1.00 (0.63, 1.61) | 0.008 | 79.1 | 5 | 0.97 (0.81, 1.17) | 0.075 | 53 |
Abbreviations: n-3 PUFA: n-3 polyunsaturated fatty acids.
Figure 5Effect of type 2 diabetes on tissue C22∶6n-3 composition compared with controls.
The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. The diamond indicates summary SMD.
Figure 6Effect of type 2 diabetes on tissue total n-3 PUFA composition compared with controls.
The combined standardized mean difference (SMD) was achieved using random-effects model. Grey square represents SMD in each study, with square size reflecting the study-specific weight and the 95% CI represented by horizontal bars. The diamond indicates summary SMD.